morphogenesis of, 1258–1259, 1259f philosophical considerations with, 1245–1246, 1246f–1247f pulmonary atresia with intact ventricular septum in, 1249–1250, 1250f–1251f straddling atrioventricular valves in, 1254–1256, 1255f–1258f unbalanced atrioventricular septal defect in, 1256–1257 physiologic principles to maximize outcome in, 1261–1270 birth, physiology immediately after, 1261–1264 clinical presentation of, 1261–1262 fetal and transitional circulation, 1262–1264 clarifications and proposed changes to, 1264–1266 parallel circulation in, 1264–1265, 1264f pulmonary and systemic blood flow, balancing, 1264f pulmonary overcirculation in, 1264f single-ventricle physiology in, 1265–1266 medical management of, 1261 staged reconstruction in guiding principles of, 1261, 1262b physiologic effects of, 1264f, 1266t–1267t serial physiologic data during, 1267t, 1268 strategies and physiologic goals of, optimal outcome and, 1261, 1262t, 1263f superior cavopulmonary connection in, 1266–1267, 1266f–1267f surgical management of, 1261 total cavopulmonary connection (Fontan procedure) in, 1268 unanticipated hypoxemia in, 1268–1270, 1268f, 1269t venovenous collaterals in, 1269–1270, 1270f–1271f Furosemide for hypertension, 1140t for systemic hypertension, in premature infants, 208f G Gadolinium-based contrast agent, 328 Galactosialidosis, cardiac involvement in, 1093 α-Galactosidase A deficiency, cardiac involvement in, 1094 Gallop rhythm, in Kawasaki disease, 982 Gangliosidoses, cardiac involvement in, 1094–1095 Gastroesophageal reflux, oral intake and, 1501 Gastrointestinal care, for prematurity, 211 Gastrointestinal system, extracardiac anomalies of, 453 Gastrostomy tube feeding, 1500 Gastrulation, 33, 34f Gata4 cardiac development and, 50–51 mutations of, 54–55, 55f Gaucher disease, cardiac involvement in, 1093–1094 Genetic factors in congenital heart disease, 49–50 prevalence of congenital heart disease and, 177–178, 178t regulating cardiac formation, 50 Genetic testing, for pulmonary hypertension, 1388 Genetics, of anomalies of aortic arch, 883–886 Genitourinary system, extracardiac anomalies of, 454 Genome-wide association studies, in congenital cardiac disease, 56–57 Genotype screening, among first-degree relatives, 1539–1540, 1540t Genotype-stratified pharmacokinetic studies, 1430 Gentamicin for blood culture-negative endocarditis, 1054t for infective endocarditis, 1053t Gerbode defect, 530–531 German Heart Institute Myocarditis Registry for Children, 1511t–1514t Giant aneurysms, in Kawasaki syndrome, 994–995 Gigantism, pituitary, cardiac involvement in, 1096 Glenn circulation, 1265–1266 Glenn shunt, bidirectional, for Ebstein malformation, 598–599 Global outreach, ethical issues in, 1478–1479 Global telemedicine, 1558 α-1,4-Glucan-6-glucosyltransferase deficiency, cardiac involvement in, 1089 Glucose, control of, in cardiopulmonary bypass, 232 Glucose-6-phosphatase deficiency, cardiac involvement in, 1087 Glucose-6-phosphatase translocase deficiency, cardiac involvement in, 1087 α-1-4-Glucosidase deficiency, cardiac involvement in, 1087–1088, 1088f Glucosylceramidosis, cardiac involvement in, 1093–1094 Glutaraldehyde cross-linked collagen, in hemostasis, 1289 Glutaraldehyde-treated bovine pericardium, 220 Glycogen storage diseases, cardiac involvement in, 1087–1089 Glycoprotein degradation disorders, cardiac involvement in, 1092–1093 Goldenhar syndrome, 1418–1419, 1418t Gordon syndrome, hypertension in, 1137 Gore-Tex suture, 220 Gradient echo imaging, 321–322 Great arteries morphology of, 6, 8f transposition of, pulmonary hypertension and, 122 Great artery flow, 320t–321t